Showing results (361-370 of 2,693) with videos related to
Sort By:
Pageof 270
Thrombosis and Haemostasis|August 19, 2016
Inflammation and thrombosis - testing the hypothesis with anti-inflammatory drug trialsRaffaele De Caterina, Emilia D'Ugo, Peter LibbyThe Journal of Clinical Investigation|October 1, 2024
Clonal hematopoiesis and atherosclerosisOhad Oren, Aeron M Small, Peter LibbyThe American Journal of Pathology|May 10, 2008
Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesisStephanie Schulte, Galina K Sukhova, Peter LibbyJournal of the American College of Cardiology|April 4, 2006
Molecular and cellular imaging of atherosclerosis: emerging applicationsFarouc A Jaffer, Peter Libby, Ralph WeisslederSeminars in Immunopathology|July 11, 2013
Monocyte heterogeneity in cardiovascular diseasePeter Libby, Matthias Nahrendorf, Filip K SwirskiCurrent Cardiovascular Imaging Reports|November 23, 2018
Coronary CTA for Surveillance of Cardiac Allograft VasculopathyNishant R Shah, Ron Blankstein, Todd Villines, et al.Current Cardiovascular Imaging Reports|June 13, 2019
Correction to: Coronary CTA for Surveillance of Cardiac Allograft VasculopathyNishant R Shah, Ron Blankstein, Todd Villines, et al.Archives of Internal Medicine|May 28, 2003
Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE studyHani Jneid, Deepak L Bhatt, Roberto Corti, et al.Cardiovascular Therapeutics|September 3, 2011
Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian CohortZanfina Ademi, Danny Liew, Bruce Hollingsworth, et al.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 26, 2010
Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registryZanfina Ademi, Danny Liew, Bruce Hollingsworth, et al.Pageof 270